Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt

2014 ◽  
Vol 22 (3) ◽  
pp. 245-253 ◽  
Author(s):  
P. Bonnard ◽  
A. Elsharkawy ◽  
K. Zalata ◽  
E. Delarocque-Astagneau ◽  
L. Biard ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Genotype 4 ◽  
Noninvasive Techniques ◽  
Hcv Genotype

Correlation Between TGF-β1 and c-MET Expression in HCV Genotype 4-Induced Liver Fibrosis

2018 ◽  
Vol 38 (12) ◽  
pp. 552-558 ◽  
Author(s):  
Ghada M. Salum ◽  
Noha G. Bader El Din ◽  
Marwa K. Ibrahim ◽  
Reham M. Dawood ◽  
Sally Farouk ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Tgf Β1

Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis

2012 ◽  
Vol 23 (1) ◽  
pp. e34-e35 ◽  
Author(s):  
Ahmed A. El Khattib ◽  
Sara M. Abdelhakam ◽  
Dalia M. Ghoraba ◽  
Wesam A. Ibrahim ◽  
Moataz M. Sayed
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Antiviral Therapy ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Advanced Liver Fibrosis

Su1427 Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-I)

2016 ◽  
Vol 150 (4) ◽  
pp. S1097
Author(s):  
Tarek I. Hassanein ◽  
Tarik Asselah ◽  
Roula B. Qaqish ◽  
Christophe Hezode ◽  
Jean-Pierre Mulkay ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Compensated Cirrhosis ◽  
And Function

scholarly journals Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project

2021 ◽  
Vol 10 (18) ◽  
pp. 4176
Author(s):  
Maria Pokorska-Śpiewak ◽  
Anna Dobrzeniecka ◽  
Małgorzata Aniszewska ◽  
Magdalena Marczyńska
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Life Experience ◽  
Real Life ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Genotype 4 ◽  
Hcv Genotype

Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of LDV/SOF (90/400 mg) for the treatment of chronic hepatitis C (CHC) genotypes 1 and 4 in children aged 12 to 17 years. Methods: We analyzed intention-to-treat (ITT) and per-protocol (PP) rates of sustained virological response (SVR), defined as undetectable HCV viral load at posttreatment week 12, in 37 participants treated with LDV/SOF according to the HCV genotype, baseline liver fibrosis, duration of treatment, and experience of the previous ineffective antiviral treatment. There were 32 patients infected with genotype 1 and 5 with genotype 4. Fourteen (38%) participants were treatment-experienced, two were coinfected with HIV, and three were cirrhotic. Two patients qualified for 24 weeks of therapy, and the remaining 35 received 12 weeks of LDV/SOF treatment. Results: The overall ITT SVR12 rate was 36/37 (97%). One patient was lost to follow-up after week 4 of therapy when his HCV RNA was undetectable. All 36 patients who completed the full protocol achieved SVR (36/36, 100%). PP analyses of SVR12 rates according to the HCV genotype, baseline liver fibrosis, duration of the treatment, and previous ineffective treatment were all 100%. A significant decrease in aminotransferase serum levels was observed in the subsequent weeks of the treatment and at SVR assessment compared to baseline. No serious adverse events were reported. Conclusions: The results of this study confirm previous observations of a suitable efficacy and safety profile of LDV/SOF for the treatment of CHC genotypes 1 and 4 in adolescents.

Impact ofOAS1Exon 7 rs10774671 Genetic Variation on Liver Fibrosis Progression in Egyptian HCV Genotype 4 Patients

2015 ◽  
Vol 28 (9) ◽  
pp. 509-516 ◽  
Author(s):  
Noha G. Bader El Din ◽  
Mohamed A. Anany ◽  
Reham M. Dawood ◽  
Marwa K. Ibrahim ◽  
Reem El-Shenawy ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Liver Fibrosis ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Fibrosis Progression

scholarly journals Impact of IL10, MTP, SOD2, and APOE Gene Polymorphisms on the Severity of Liver Fibrosis Induced by HCV Genotype 4

Viruses ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 714
Author(s):  
Amr Ali Hemeda ◽  
Amal Ahmad Mohamed ◽  
Ramy Karam Aziz ◽  
Mohamed S. Abdel-Hakeem ◽  
Marwa Ali-Tammam
Keyword(s):  
Liver Fibrosis ◽  
Viral Entry ◽  
Microsomal Triglyceride Transfer Protein ◽  
Interleukin 10 ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Egyptian Patients ◽  
Patients At Risk ◽  
Metabolic Oxidative Stress ◽  
Encoding Genes

Complications of hepatitis C virus (HCV) chronic infection cause ~400,000 deaths worldwide annually. One complication, liver fibrosis, is influenced by host genetic factors. Genes influencing fibrosis include immune, metabolic, oxidative stress, and viral entry genes, such as interleukin 10 (IL10), microsomal triglyceride-transfer protein (MTP), superoxide dismutase-2 (SOD2), and apolipoprotein E (APOE)-encoding genes, respectively. Thus, correlating variations in these genes with HCV-induced fibrosis represents an attractive biomarker for the prognosis of fibrosis severity in chronically infected patients. Here, we aimed to test whether polymorphisms in IL10, MTP, SOD2, and APOE genes correlated with the severity of fibrosis induced by HCV genotype 4 (HCV-gt4) in a cohort of chronically infected Egyptian patients. Our results demonstrate a significant association between the severity of fibrosis and specific SNPs in IL-10, SOD2, and ApoE-encoding genes. Haplotype-combination analysis for IL10, MTP, SOD2, and APOE showed statistically significant associations between specific haplotype combinations and fibrosis severity. Identifying biomarkers correlating with the severity of HCV-gt4-induced fibrosis would significantly impact precision prophylaxis and treatment of patients at risk.

Diagnostic accuracy of the γ-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4

Gut ◽  
2016 ◽  
Vol 65 (9) ◽  
pp. 1577-1578 ◽  
Author(s):  
Yusuke Shimakawa ◽  
Philippe Bonnard ◽  
Mohamed El Kassas ◽  
Mohamed Abdel-Hamid ◽  
Gamal Esmat ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Diagnostic Accuracy ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Egyptian Patients ◽  
Glutamyl Transpeptidase
Sign in / Sign up

Export Citation Format

Share Document